Unlocking the science: How weight loss medication works and its efficacy
The lowdown on the reliability levels of weight loss drugs.
Written by
Carol Mateus and Louis Talay
Medically reviewed by
Dr Ben Condon
Last Updated
September 15, 2023
3
min read
5
References
Share
link copied

Weight loss medications have been all over the news and social media recently, so chances are you’ve heard of them.
Whether you’re all for the use of weight loss medication, or are still a bit sceptical, it’s helpful to understand how these medications actually work, as well as how effective and safe they are for overweight and obese people.
Read as we give you the lowdown on the safety and reliability levels of weight loss medications.
How do these new weight loss medications work?
Originally developed to treat type 2 diabetes, these medications are made up of a molecule that mimics glucagon-like-peptide-1 (GLP-1) activity in the body. GLP-1 is an appetite hormone that your body naturally produces to help regulate hunger.
GLP-1 also stimulates the pancreas to release more insulin when needed, slowing down digestion, and minimising the secretion of glucose into the bloodstream — all of which helps to control blood sugar levels [1].
However, during the testing phase, it became clear that patients being treated with this class of medication weren’t just treating their diabetes. They were also losing a significant amount of weight.
But how? Let’s see what the science says.
On one hand, there’s the physiological effect of slower digestion, which makes you feel fuller for longer, helping to reduce your caloric intake. But the medication also affects people on a neurological level.
They suppress appetite by modifying neural pathways involved in reward, motivation, and addiction — and this is what’s believed to be most responsible for the drug’s unprecedented outcomes [2].
The reason for this is still not entirely clear, but logic suggests that it is related to the pathological pathway behind obesity, which starts with desire.
While we know that humans can use their brains to satisfy desires while navigating physiological changes — for example, by replacing 3 meals with continuous snacking to accommodate a smaller stomach after gastric band surgery — there’s little evidence of us retrieving a desire after it has been neurologically suppressed.
The latter appears to be corroborated by a recent large-scale clinical study that found that these medications had the same appetite-suppressing effect on the brain at the end of the 68-week trial as they did in the early stages [3].
Nevertheless, it is by inducing both a physiological and neurological response that these medications are able to suppress human appetite and, as a result, aid with significant weight loss.
How effective is this weight loss medication?
While theoretical explanations of the efficacy of these medications in inducing weight loss excited everyone, there was a sense that the hype was too good to be true.
Meaningful assessments could only be made once sufficient data from reliable studies became available — and that’s exactly what happened in 2015 when a double-blind randomised controlled study became the first confirmation of the drug’s efficacy.
In this study, 611 patients were split into 2 groups: one taking a placebo combined with intensive behavioural therapy and a low calorie diet, and the other one receiving weekly high-dose injections of a weight loss drug for 68 weeks [4]. By the end of the study, the results were promising:
- Patients in the treatment group lost an average of 16% of their body weight compared to the placebo group that lost a mean of 5.7% of their body weight.
- Nearly 90% of patients in the treatment group lost at least 5% of their body weight.
- More than 50% of patients lost at least 15% of their body weight.
- Greater improvement was registered in the treatment group than the control group across all cardio-metabolic biomarkers, including blood pressure, triglycerides, fasting plasma glucose along with higher scores on the SF-36 quality of life questionnaire. [4]
It’s important to note that these patients received lifestyle counselling approximately once a month. But since no other details on these sessions were provided, we can reasonably deduce that they weren’t guided through a diet and/or exercise program.
Though this might seem irresponsible, it was actually a strength of the study design, as it allowed future health stakeholders, such as ourselves, to determine that all of the weight loss observed in the study was attributable to the medication rather than being confounded by lifestyle interventions.
Are they safe?
The short answer is yes, the medication has an excellent safety profile.
Although some patients experience adverse events, the vast majority of these are mild to moderate and affect the gastrointestinal system — think nausea, vomiting, and diarrhoea — and such effects subside as your body adjusts to the medication.
Moreover, while no one enjoys experiencing symptoms like these — even if they only occur in the short-term, the discomfort is far outweighed by the reward of tackling obesity and its comorbidities.
Some people might also become alarmed by the figures on serious side effects reported in studies like the 2015 Pi-Sunyer et al. clinical trial we mentioned before. But here’s the thing: these figures always need to be compared to those of the control group.
For example, in the Pi-Sunyer et al study, 6.2% of treatment patients experienced serious adverse events, but so did 5% of patients in the control group. And although 1 treatment patient died from hypertensive heart disease, 2 placebo patients also died — one from pulmonary fibrosis and the other from cardiorespiratory arrest.
Another 2 large-scale trials of the medication have also observed a negligible difference in the incidence of serious adverse events between treatment and control groups, stressing that all events, including deaths, were caused by issues that already existed before the study [6][3].
These facts shouldn’t scare you about the potential side effects of the medications. On the contrary, they should remind you of the dangers of living with obesity.
Yes, receiving guided ongoing treatment might result in some uncomfortable adverse events for a while, but if you stick with it, you have a good chance of losing a substantial amount of weight and lowering serious health risk factors.
This is especially true if you take the medication as a part of a holistic weight loss plan like Juniper’s Weight Reset Program, which provides you with medical advice, health coaching, and weight loss drugs, so you can effectively, safely, and confidently navigate your weight loss journey.
It’s more than just weight loss
Thousands of Australian women have found new confidence with Juniper.
No items found.
Give this a go:
No items found.
Articles you might like:
No items found.
References
- Tran, K., Park, Y., Pandya, S., et al. (2017) Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. American Health & Drug Benefits, 10(4), 178-188.
- Müller, T., Finan, B., Bloom, S., et al. (2019) Glucagon-like peptide 1 (GLP-1), Mol Metab, 30:72-130.
- Wilding, J., Batterham, R., Calanna, S., et al. (2021). Once-weekly Semaglutide in adults with overweight or obesity. N Engl J Med, 384: 989-1002
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905697/
- Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015) A randomised, controlled trial of 3.0mg of Liraglutide in weight management. N Engl J Med, 373:11-12
- Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14): 1414-1425.
See all
Filed under: